Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

被引：2
|
作者：
Poveda, Andres
Lheureux, Stephanie
Colombo, Nicoletta
Cibula, David
Lindemann, Kristina
Weberpals, Johanne I.
Bjurberg, Maria
Oaknin, Ana
Sikorska, Magdalena
Gonzalez Martin, Antonio
Madry, Radoslaw
Jesus Rubio, Maria
Ledermann, Jonathan A.
Davidson, Richard
Blakeley, Christopher
Bennett, James
Brown, Jessica
Skof, Erik
机构：
[1] Initia Oncol, Valencia, Spain
[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada
[3] IEO Ist Europeo Oncol, Milan, Italy
[4] Charles Univ Hosp, Fac Med 1, Prague, Czech Republic
[5] Oslo Univ Hosp, Oslo, Norway
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Lund Univ, Skane Univ Hosp, Lund, Sweden
[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[9] Olsztyn Prov Specialist Hosp, Olsztyn, Poland
[10] Clin Univ Navarra, Madrid, Spain
[11] Lords Med Univ Karol Marcinkowski, Clin Hosp Transfigurat, Poznan, Poland
[12] Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain
[13] UCL, UCL Canc Inst, London, England
[14] UCL Hosp, London, England
[15] AstraZeneca, Cambridge, England
[16] Inst Oncol Ljubljana, Ljubljana, Slovenia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5545
引用
收藏
页数：4
相关论文
共 50 条
  • [41] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
    Friedlander, M.
    Gebski, V.
    Gibbs, E.
    Bloomfield, R.
    Hilpert, F.
    Wenzel, L. B.
    Joly, F.
    Eek, D.
    Rodrigues, M.
    Clamp, A.
    Penson, R.
    Provencher, D.
    Korach, J.
    Huzarski, T.
    Vidal, L.
    Salutari, V.
    Scott, C.
    Nicoletto, M. O.
    Tamura, K.
    Pujade-Lauraine, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941
  • [42] Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis
    Matulonis, U. A.
    Penson, R. T.
    Domchek, S. M.
    Kaufman, B.
    Audeh, M. W.
    Kaye, S. B.
    Molife, L. R.
    Mann, H.
    Robertson, J.
    Coleman, R. L.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 8 - 9
  • [43] A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
    Lee, Yong Jae
    Lim, Myong Cheol
    Kim, Byoung Gie
    Ngoi, Natalie Yl
    Choi, Chel Hun
    Park, Sang Yoon
    Tan, David S. P.
    Go, Yunjung
    Lee, Jung Yun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (02) : 1 - 7
  • [44] Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial EDITORIAL COMMENT
    Ledermann, Jonathan
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Spencer, Stuart
    Dougherty, Brian
    Orr, Maria
    Hodgson, Darren
    Barrett, J. Carl
    Matulonis, Ursula
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2014, 69 (10) : 594 - 596
  • [45] Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
    Mathews, Cara Amanda
    Simpkins, Fiona
    Cadoo, Karen Anne
    Liu, Ying L.
    Provencher, Diane M.
    McCormick, Colleen
    ElNaggar, Adam
    Altman, Alon D.
    Gilbert, Lucy
    Black, Destin
    Kabil, Nashwa
    Bennett, James
    Munley, Jiefen
    Yu, Judy
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [47] Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
    Nie, Jing
    Wu, Huina
    Sun, Lei
    Ding, Yanjiao
    Luan, Yepeng
    Wu, Jiyong
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [48] Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.
    Lee, Jung-Yun
    Kim, Jae-Weon
    Kim, Byoung-Gie
    Kim, Sang Wun
    Kim, Hee Seung
    Kim, Se Ik
    Lim, Myong Cheol
    Choi, Chel Hun
    Ngoi, Natalie
    Tan, David Shao Peng
    Kim, Yoo Na
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17579 - E17579
  • [49] Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.
    Ma, Ding
    Gao, Qing-Lei
    Zhu, Jianqing
    Zhao, Weidong
    Huang, Yi
    An, Ruifang
    Zheng, Hong
    Qu, Pengpeng
    Wang, Li
    Zhou, Qi
    Wang, Danbo
    Lou, Ge
    Wang, Jing
    Low, John
    Kong, Beihua
    Yin, Rutie
    Xie, Xing
    Liu, Jihong
    Sun, Wei
    Zang, Rongyu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17578 - E17578
  • [50] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 727 - 727
12345